FDA and CMS have agreed to review Medtronic PLC’s Symplicity renal denervation hypertension treatment system concurrently as part of the agencies’ parallel review pilot program, the company announced March 6.
The device is one of the first, and perhaps the most high profile, to participate in the program, in which...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?